Methyl-CpG-binding domain 3 inhibits epithelial|[ndash]|mesenchymal transition in pancreatic cancer cells via TGF-|[beta]||[sol]|Smad signalling
Min Xu,Junbo He,Jie Li,Wen Feng,Hailang Zhou,Hong Wei,Meng Zhou,Ying Lu,Jian Zeng,Wanxin Peng
DOI: https://doi.org/10.1038/bjc.2016.397
IF: 9.075
2016-01-01
British Journal of Cancer
Abstract:Pancreatic cancer is the fourth leading cause of cancer death in both men and women in the United States, with a 5-year survival rate limited to ~5% (Klein, 2012). Traditional remedies such as surgery, chemotherapy, and/or radiation result in a poor clinical outcome in the past decades (Amundadottir, 2016). Lack of early diagnoses and effective interventions lead to the poor prognosis of patients (Del Chiaro et al, 2014). Therefore, it is necessary for us to look for the specific indicator and diagnosis of pancreatic cancer in the early stage. Pancreatic cancer is characterised by early invasion and metastasis (Thota et al, 2014). It is reported that EMT has a critical role in cancer progression and metastasis (Cai et al, 2016), including pancreatic cancer (Wang et al, 2013). EMT results in losing cell adhesion and gaining migration capacity via epigenetic modifications and altered stromal interactions (Gunasinghe et al, 2012; Tam and Weinberg, 2013). Previous studies have proven that epigenetic modifications, especially DNA methylation, play an important role in pancreatic cancer (Yokoyama et al, 2016; Zagorac et al, 2016). DNA methylation controls gene expression by recruiting proteins involved in transcriptional repression (Wood and Zhou, 2016). The methyl-CpG-binding domain proteins (MBDs) read and bind methylated DNA, recruiting additional chromatin remodelling proteins that can modify histones to form compact silent chromatin (Choi et al, 2013). MBD3 is an important member of MBDs, which are important constituents of the DNA methylation machinery (Menafra and Stunnenberg, 2014). MBD3 is an essential subunit of the nucleosome remodelling and deacetylase (NuRD) complex, involved in chromatin remodelling (Zhang et al, 2016). Also, removing MBD3 allows deterministic iPSC generation (Brumbaugh and Hochedlinger, 2013). Moreover, several studies have demonstrated that MBD3 is downregulated in gastric carcinogenesis (Pontes et al, 2014), colon, and lung cancer (Zhu et al, 2004). However, the role of MBD3 in pancreatic cancer cells remains to be clarified. In this study, we found that MBD3 expression had meaningful difference in pancreatic cancer tissues, and was critical for the ability of migration and invasion in pancreatic cancer cells in vitro. Furthermore, it was found that MBD3 inhibited EMT in pancreatic cancer cells probably via TGF-β/Smad signalling. All these findings for the first time prove that MBD3 may be a suppressor in pancreatic cancer progression. In this study, we find that MBD3 may function as an anti-oncogene in pancreatic cancer. We for the first time find that MBD3 suppresses EMT in pancreatic cancer cells probably via TGF-β/Smad signalling. Importantly, we confirm that MBD3 is downregulated in human pancreatic cancer at both mRNA and protein levels, and acts as an independent prognostic factor for patient outcome. All these findings suggest that MBD3 may be a candidate for diagnosis and prognosis of pancreatic cancer. Our previous study focused on examining the activity of MBD3 binding to hypermethylated CpG islands of LIN28A promoter in pancreatic cancer cells (Xu et al, 2016). In this study, we concentrated on the clinical relevance of MBD3 expression and its roles in the growth and EMT of pancreatic cancer cells. MBD3 expression is described for the first time in pancreatic cancer tissues in different clinicopathological features, at different tumour stages, and is associated with the outcome of patients. Previous studies have determined that MBD3 expression is downregulated in gastric carcinogenesis (Pontes et al, 2014), colon, and lung cancer (Zhu et al, 2004), indicating that reduced MBD3 expression is a potential marker of the carcinogenesis process. In this study, MBD3 expression is lowest in pancreas adenocarcinoma ductal, and reduces progressively with the increase of clinical stage in pancreatic cancer. It is indicated that the reduced MBD3 expression may have an important role in the development of pancreatic cancer and may be a biomarker for the detection of cancer development and progression, and directly associated with clinicopathological features. In addition, patients with lower MBD3 levels survive significantly less than those with higher levels, suggesting that downregulation of MBD3 expression is associated with the poor outcome of patients. It is implied that MBD3 may be a suppressor in pancreatic cancer progression. It is well-known that EMT has an important role in pancreatic cancer progression (Wang et al, 2013). In this study, we identify that MBD3 knockdown upregulates mesenchymal markers and downregulates the epithelial marker expression of E-cadherin. Our findings confirm that MBD3 has a significant role in inhibiting EMT in pancreatic cancer cells. In addition, during the EMT process, cancer cells not only gain enhanced the ability of migration and invasion but also acquire cancer stem cell traits (Scheel and Weinberg, 2012; Du et al, 2016). Previous reports have shown that MBD3 knockout results in increasing the stemness of cells (Rais et al, 2013). Therefore, we speculate that inhibition of MBD3 on EMT might be partially via regulating stemness of cancer cells. Previous study has demonstrated that TGF-β/Smad signalling is operational in pancreatic cancer (Togashi et al, 2014). When TGF-β is activated, Smad2 is phosphorylated and undergoes dimerisation with Smad3, thus allowing its translocation into nucleus in cancer cells, promoting the EMT progress (Liu et al, 2012; Liu et al, 2015). In this study, we find that MBD3 knockdown induces upregulating the TGF-β, p-Smad2/3; MBD3 overexpression results in downregulating the TGF-β, p-Smad2/3 in pancreatic cancer cells. Previously, MBD3 is a component of the Mi-2 autoantigen (Mi-2)/nucleosome remodelling and histone deacetylase (NuRD)-HDAC complex (Mi-2/nuclesome remodelling and deacetylase; Crook et al, 2006). MBD3 acts as a transcriptional repressor by recruiting HDACs, and is not only released from cancer-selective promoter of the histone deacetylase inhibitors (HDI) upregulated p21WAF1/Cip1 gene but also recruited to that of the HDI-downregulated ErbB2 gene, resulting in inhibiting the growth and survival of cancer cells (Noh et al, 2005). In addition, Snail is an important effector for the ability of invasion, forming Snail/HDAC1/HDAC2 repressor complex, and acting through transcriptional repression of E-cadherin during the EMT progress (von Burstin et al, 2009). Thus, it is reasonable to believe that Snail/HDAC1/HDAC2 repressor complex might be involved in inhibition of MBD3 on EMT. Furthermore, it is reported that HDAC1 is required for TGF-β-induced EMT (Lei et al, 2010), which might establish a link between MBD3 and TGF-β signalling. It is implied that MBD3 as a HDAC1 inhibiter suppress EMT probably via TGF-β/Smad signalling. Although, whether that the above two pathways are separated or associated remains unidentified, it is confirmed that MBD3 impair TGF-β/Smad signalling, and suppress EMT in pancreatic cancer cells. Importantly, HDI have been reported to be used in clinic, silencing of MBD3 abrogates the HDI-induced gene regulation and growth inhibition in cancer cells but not in normal cells (Noh et al, 2005). It is suggested that MBD3 has an important role in treating cancer and may be a potential therapeutic target candidate to pancreatic cancer. In summary, our study provides proof that MBD3 inhibits EMT in pancreatic cancer cells probably through downregulating TGF-β/Smad signalling. All these findings suggest that MBD3 is a potential biomarker for diagnostics and prognosis of pancreas colloid type carcinoma and pancreatic cancer at stage 3 and stage 4. The authors declare no conflict of interest. This study was supported by grants from the National Natural Science Foundation of China (81672402, 81472333 and 81372718) and the Natural Science Foundation of Jiangsu Province (BK20131247).